Dr. Tania Bubela, PhD

Who we are:

Case study research allows for the identification of causal mechanisms underlying complex, systems-dependent phenomena-like innovation. However, determining that there is a causal effect does not provide the causal story.

Data governance in support of LHS initiatives for precision oncology implicates an intricate web of statutes, regulations, guidance, policies, and practices.

Precision oncology is premised on large-scale, annotated 'omics data that improve our understanding of mutations, treatment response, resistance, quality of life and side effects, within an LHS.

Confronted with value uncertainty and high patient demand, payers are considering managed access approaches that re-evaluate adopted technologies or that manage the risk of early patient access through risk-sharing arrangements between developers and healthcare systems.